Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway.

[1]  D. Freimark,et al.  Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy , 2020, Cardiovascular Diabetology.

[2]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[3]  J. Badimón,et al.  Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance , 2019, International journal of molecular sciences.

[4]  Akshay S. Desai,et al.  Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. , 2019, Circulation.

[5]  M. Sabatine,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply. , 2019, The New England journal of medicine.

[6]  Ji Li,et al.  Mitochondrial Complex I Inhibition by Metformin Limits Reperfusion Injury , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[7]  D. Aravot,et al.  The Role of Heme Oxygenase 1 in the Protective Effect of Caloric Restriction against Diabetic Cardiomyopathy , 2019, International journal of molecular sciences.

[8]  Yi‐Jen Chen,et al.  Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats , 2019, International journal of molecular sciences.

[9]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[10]  J. Falck,et al.  High-fat diet-induced obesity and insulin resistance in CYP4a14-/- mice is mediated by 20-HETE. , 2018, American journal of physiology. Regulatory, integrative and comparative physiology.

[11]  V. Vallon,et al.  Development of SGLT1 and SGLT2 inhibitors , 2018, Diabetologia.

[12]  J. McMurray,et al.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.

[13]  K. Cohen,et al.  Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving ‘SIRT1 and PGC-1α’ , 2018, Cardiovascular Diabetology.

[14]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[15]  T. Davis,et al.  Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. , 2017, Clinical therapeutics.

[16]  Eun-Hee Kim,et al.  The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts , 2017, Heart and Vessels.

[17]  S. Persaud,et al.  Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential , 2017, Pharmacology & therapeutics.

[18]  A. Pozzi,et al.  Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans , 2017, Diabetologia.

[19]  R. Tal-Singer,et al.  Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers , 2017, Chest.

[20]  L. Tarnow,et al.  Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial , 2017, European journal of heart failure.

[21]  C. Bode,et al.  Diabetic Cardiomyopathy: Does the Type of Diabetes Matter? , 2016, International journal of molecular sciences.

[22]  H. Swanson,et al.  Current and Emerging Uses of Statins in Clinical Therapeutics: A Review , 2016, Lipid insights.

[23]  M. Monami,et al.  Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials , 2016, Advances in Therapy.

[24]  Zhiqiang Ma,et al.  Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy? , 2016, Cellular and Molecular Life Sciences.

[25]  R. Coronel,et al.  Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits , 2016, Diabetologia.

[26]  P. Ponikowski,et al.  2016 ESC and ACC/AHA/HFSA heart failure guideline update — what is new and why is it important? , 2016, Nature Reviews Cardiology.

[27]  P. Pesce,et al.  EETs and HO-1 cross-talk. , 2016, Prostaglandins & other lipid mediators.

[28]  J. Falck,et al.  PGC-1 alpha regulates HO-1 expression, mitochondrial dynamics and biogenesis: Role of epoxyeicosatrienoic acid. , 2016, Prostaglandins & other lipid mediators.

[29]  A. Farcomeni,et al.  Aging‐Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation , 2016, Journal of the American Heart Association.

[30]  M. Wang,et al.  EETs/sEH in diabetes and obesity-induced cardiovascular diseases. , 2016, Prostaglandins & other lipid mediators.

[31]  K. Anstrom,et al.  Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[32]  P. Umbarkar,et al.  Mitochondrial Peroxiredoxin-3 protects against hyperglycemia induced myocardial damage in Diabetic cardiomyopathy. , 2016, Free radical biology & medicine.

[33]  S. Gupta,et al.  Cardioprotective effects of rutin via alteration in TNF-α, CRP, and BNP levels coupled with antioxidant effect in STZ-induced diabetic rats , 2016, Molecular and Cellular Biochemistry.

[34]  Z. Darżynkiewicz,et al.  Epoxyeicosatrienoic Acids Regulate Adipocyte Differentiation of Mouse 3T3 Cells, Via PGC-1α Activation, Which Is Required for HO-1 Expression and Increased Mitochondrial Function. , 2016, Stem cells and development.

[35]  S. Baumgartner-Parzer,et al.  Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[36]  Joseph Cheriyan,et al.  Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. , 2016, British journal of clinical pharmacology.

[37]  Jennifer G. Robinson,et al.  Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. , 2016, The lancet. Diabetes & endocrinology.

[38]  N. Brown,et al.  Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition , 2016, Circulation.

[39]  A. Lenzi,et al.  PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial. , 2016, The Journal of clinical endocrinology and metabolism.

[40]  N. Abraham,et al.  Oxidized HDL is a potent inducer of adipogenesis and causes activation of the Ang-II and 20-HETE systems in human obese females. , 2016, Prostaglandins & other lipid mediators.

[41]  G. Liang,et al.  Rutin Inhibits Neuroinflammation and Provides Neuroprotection in an Experimental Rat Model of Subarachnoid Hemorrhage, Possibly Through Suppressing the RAGE–NF-κB Inflammatory Signaling Pathway , 2016, Neurochemical Research.

[42]  Akshay S. Desai,et al.  Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction , 2016, Circulation. Heart failure.

[43]  K. Swedberg,et al.  Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial , 2015, European journal of heart failure.

[44]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[45]  T. Peng,et al.  Abstract 13631: Therapeutic Inhibition of Mitochondrial Reactive Oxygen Species With Mito-tempo Reduces Diabetic Cardiomyopathy , 2015, Circulation.

[46]  B. Merkely,et al.  The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus , 2015, Cardiovascular Diabetology.

[47]  J. Keaney,et al.  Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. , 2015, European heart journal.

[48]  Rick B. Vega,et al.  Mitochondrial biogenesis and dynamics in the developing and diseased heart , 2015, Genes & development.

[49]  K. Margulies,et al.  Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+–Glucose Cotransport , 2015, Journal of the American Heart Association.

[50]  Y. Duan,et al.  N-Acetyl Cysteine improves the diabetic cardiac function: possible role of fibrosis inhibition , 2015, BMC Cardiovascular Disorders.

[51]  N. Abraham,et al.  Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasis. , 2015, Prostaglandins & other lipid mediators.

[52]  O. Irtyuga,et al.  [The level of circulating PGC1a in cardiovascular disease]. , 2015, Biomeditsinskaia khimiia.

[53]  H. Krum,et al.  Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy , 2015, The Lancet.

[54]  G. Heinze,et al.  Free fatty acid availability is closely related to myocardial lipid storage and cardiac function in hypoglycemia counterregulation. , 2015, American journal of physiology. Endocrinology and metabolism.

[55]  Anindita Das,et al.  PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. , 2015, Pharmacology & therapeutics.

[56]  Zheng Wen,et al.  Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II. , 2015, Cardiovascular research.

[57]  J Cheriyan,et al.  The role of epoxyeicosatrienoic acids in the cardiovascular system , 2015, British journal of clinical pharmacology.

[58]  P. Ponikowski,et al.  Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease , 2015, European journal of heart failure.

[59]  J. Alkaabi,et al.  Dapagliflozin reduces the amplitude of shortening and Ca2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats , 2015, Molecular and Cellular Biochemistry.

[60]  M. Lai,et al.  Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study. , 2015, The Journal of clinical endocrinology and metabolism.

[61]  B. Zinman,et al.  Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis , 2014, The Lancet.

[62]  Heidi N. Fridolfsson,et al.  High-fat diet-induced impairment of skeletal muscle insulin sensitivity is not prevented by SIRT1 overexpression. , 2014, American journal of physiology. Endocrinology and metabolism.

[63]  T. Mazzone,et al.  Adipose tissue changes in obesity and the impact on metabolic function. , 2014, Translational research : the journal of laboratory and clinical medicine.

[64]  N. Frangogiannis,et al.  Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. , 2014, Translational research : the journal of laboratory and clinical medicine.

[65]  K. Tomer,et al.  Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity , 2014, Journal of Lipid Research.

[66]  S. Tacconelli,et al.  Inside epoxyeicosatrienoic acids and cardiovascular disease , 2014, Front. Pharmacol..

[67]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[68]  M. Woodward,et al.  Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data , 2014, The Lancet.

[69]  N. Ozaki,et al.  KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state. , 2014, The Journal of endocrinology.

[70]  F. Eitner,et al.  Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury , 2014, Journal of cardiovascular pharmacology.

[71]  R. Ritchie,et al.  Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. , 2014, Pharmacology & therapeutics.

[72]  D. Grobbee,et al.  Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. , 2014, JAMA.

[73]  T. Edvardsen,et al.  Risk prediction of ventricular arrhythmias and myocardial function in Lamin A/C mutation positive subjects. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[74]  R. Kornowski,et al.  Heme Oxygenase-1 Induction Improves Cardiac Function following Myocardial Ischemia by Reducing Oxidative Stress , 2014, PloS one.

[75]  M. Latronico,et al.  Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. , 2014, Journal of the American College of Cardiology.

[76]  J. Cutler,et al.  Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial , 2014, Diabetes Care.

[77]  F. Lamoureux,et al.  Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases , 2014, Expert opinion on drug discovery.

[78]  H. Koepsell,et al.  Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. , 2014, American journal of physiology. Renal physiology.

[79]  J. McMurray,et al.  Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). , 2013, Journal of the American College of Cardiology.

[80]  K. Connelly,et al.  DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. , 2013, Cardiovascular therapeutics.

[81]  G. Favero,et al.  Abstract 34: CYP2J2 Targeting to Endothelial Cells Attenuates Adiposity and Vascular Dysfunction in Mice Fed a High Fat Diet by Reprogramming Adipocyte Phenotype , 2013 .

[82]  C. Lord,et al.  Cardiac Fibroblast-Dependent Extracellular Matrix Accumulation Is Associated with Diastolic Stiffness in Type 2 Diabetes , 2013, PloS one.

[83]  O. Pappo,et al.  Bone Marrow and Nonbone Marrow Toll Like Receptor 4 Regulate Acute Hepatic Injury Induced by Endotoxemia , 2013, PloS one.

[84]  N. Abraham,et al.  Increased HO-1 Levels Ameliorate Fatty Liver Development Through a Reduction of Heme and Recruitment of FGF21 , 2013, Obesity.

[85]  P. Lijnen,et al.  Oxidative stress and transforming growth factor-β1-induced cardiac fibrosis. , 2013, Cardiovascular & hematological disorders drug targets.

[86]  Hau D. Le,et al.  Epoxyeicosanoids promote organ and tissue regeneration , 2013, Proceedings of the National Academy of Sciences.

[87]  Piotr Ponikowski,et al.  EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) , 2013, European journal of heart failure.

[88]  Yao Sun,et al.  Platelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts. , 2013, American journal of physiology. Heart and circulatory physiology.

[89]  D. de Zeeuw,et al.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[90]  Rui Li,et al.  Cardiac-specific overexpression of CYP2J2 attenuates diabetic cardiomyopathy in male streptozotocin-induced diabetic mice. , 2013, Endocrinology.

[91]  A. Della Corte,et al.  Cardiac Fibroblast-Derived Extracellular Matrix (Biomatrix) as a Model for the Studies of Cardiac Primitive Cell Biological Properties in Normal and Pathological Adult Human Heart , 2013, BioMed research international.

[92]  Biljana Skrbic,et al.  Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli , 2013, The FEBS journal.

[93]  J. Falck,et al.  Cyclooxygenase-2 dependent metabolism of 20-HETE increases adiposity and adipocyte enlargement in mesenchymal stem cell-derived adipocytes , 2013, Journal of Lipid Research.

[94]  Mei Yin,et al.  Investigation of the Protective Effects of Phlorizin on Diabetic Cardiomyopathy in db/db Mice by Quantitative Proteomics , 2013, Journal of diabetes research.

[95]  D. Ansley,et al.  Oxidative stress and myocardial injury in the diabetic heart , 2013, The Journal of pathology.

[96]  B. Patel,et al.  Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. , 2012, European journal of pharmacology.

[97]  Chao Liu,et al.  Curcumin Alleviates Diabetic Cardiomyopathy in Experimental Diabetic Rats , 2012, PloS one.

[98]  R. Kornowski,et al.  Endothelial progenitor cell function inversely correlates with long-term glucose control in diabetic patients: association with the attenuation of the heme oxygenase-adiponectin axis. , 2012, The Canadian journal of cardiology.

[99]  M. Sacristán,et al.  Drugs for preventing lung cancer in healthy people. , 2012, The Cochrane database of systematic reviews.

[100]  A. Waller,et al.  Novel link between inflammation and impaired glucose transport during equine insulin resistance. , 2012, Veterinary immunology and immunopathology.

[101]  D. Mann,et al.  Diabetic cardiomyopathy: bench to bedside. , 2012, Heart failure clinics.

[102]  N. Iqbal,et al.  Dapagliflozin monotherapy in drug‐naïve patients with diabetes: a randomized‐controlled trial of low‐dose range , 2012, Diabetes, obesity & metabolism.

[103]  E. Abel,et al.  Insulin resistance: metabolic mechanisms and consequences in the heart. , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[104]  F. Gribble.  The gut endocrine system as a coordinator of postprandial nutrient homoeostasis , 2012, Proceedings of the Nutrition Society.

[105]  L. Rodella,et al.  Heme Oxygenase Gene Targeting to Adipocytes Attenuates Adiposity and Vascular Dysfunction in Mice Fed a High-Fat Diet , 2012, Hypertension.

[106]  J. Falck,et al.  EET agonist prevents adiposity and vascular dysfunction in rats fed a high fat diet via a decrease in Bach 1 and an increase in HO-1 levels. , 2012, Prostaglandins & other lipid mediators.

[107]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[108]  Alan G. E. Wilson,et al.  LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial , 2012, Clinical pharmacology and therapeutics.

[109]  K. Tomer,et al.  Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. , 2012, Atherosclerosis.

[110]  A. Leite-Moreira,et al.  Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment , 2012, Heart Failure Reviews.

[111]  D. Neglia,et al.  Cobalt-Protoporphyrin Improves Heart Function by Blunting Oxidative Stress and Restoring NO Synthase Equilibrium in an Animal Model of Experimental Diabetes , 2012, Front. Physio..

[112]  M. Fernández,et al.  Inflammation and type 2 diabetes. , 2012, Diabetes & metabolism.

[113]  V. Woo,et al.  Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin , 2012, Annals of Internal Medicine.

[114]  L. Maier,et al.  Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. , 2012, Pharmacology & therapeutics.

[115]  M. Woodward,et al.  Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds , 2012, Diabetologia.

[116]  L. Rydén,et al.  Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: A report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study , 2012, Diabetes & vascular disease research.

[117]  R. Ritchie,et al.  Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes , 2012, Diabetologia.

[118]  P. Heidenreich,et al.  Role of Heart Rate as a Marker and Mediator of Poor Outcome for Patients with Heart Failure , 2012, Current Heart Failure Reports.

[119]  I. Skoularigis,et al.  TLR4 gene polymorphisms: evidence for protection against type 2 diabetes but not for diabetes-associated ischaemic heart disease. , 2011, European journal of endocrinology.

[120]  D. Ornitz,et al.  FGF10/FGFR2b signaling is essential for cardiac fibroblast development and growth of the myocardium , 2011, Development.

[121]  N. Chen,et al.  Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences , 2011, Basic Research in Cardiology.

[122]  Xin A. Zhang,et al.  The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. , 2011, Advanced drug delivery reviews.

[123]  M. Zou,et al.  Improvement of Cardiac Functions by Chronic Metformin Treatment Is Associated With Enhanced Cardiac Autophagy in Diabetic OVE26 Mice , 2011, Diabetes.

[124]  F. Haj,et al.  Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance , 2011, Proceedings of the National Academy of Sciences.

[125]  D. Clegg,et al.  Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. , 2011, The Journal of clinical investigation.

[126]  A. Shehzad,et al.  New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases , 2011, European journal of nutrition.

[127]  D. Macintyre,et al.  Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension. , 2011, European journal of pharmacology.

[128]  E. Jacobs,et al.  Stable EET urea agonist and soluble epoxide hydrolase inhibitor regulate rat pulmonary arteries through TRPCs , 2011, Hypertension Research.

[129]  K. Walsh,et al.  Adipokines in inflammation and metabolic disease , 2011, Nature Reviews Immunology.

[130]  J. Falck,et al.  Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury , 2011, British journal of pharmacology.

[131]  N. Câmara,et al.  Induction of Heme Oxygenase-1 Can Halt and Even Reverse Renal Tubule-Interstitial Fibrosis , 2010, PloS one.

[132]  L. Rodella,et al.  Adipocyte Heme Oxygenase-1 Induction Attenuates Metabolic Syndrome in Both Male and Female Obese Mice , 2010, Hypertension.

[133]  Judy W. M. Cheng,et al.  Cardiology: Pharmacologic Management of Heart Failure with Preserved Ejection Fraction , 2010 .

[134]  E. Ravussin,et al.  The NALP3/NLRP3 Inflammasome Instigates Obesity-Induced Autoinflammation and Insulin Resistance , 2010, Nature Medicine.

[135]  A. Young,et al.  Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. , 2010, The American journal of cardiology.

[136]  N. Abraham,et al.  CYP4A2-Induced Hypertension Is 20-Hydroxyeicosatetraenoic Acid- and Angiotensin II-Dependent , 2010, Hypertension.

[137]  P. Ponikowski,et al.  EURObservational Research Programme: The Heart Failure Pilot Survey (ESC‐HF Pilot) , 2010, European journal of heart failure.

[138]  J. Gimble,et al.  Regulation of adipogenesis by natural and synthetic REV-ERB ligands. , 2010, Endocrinology.

[139]  E. Ferrannini,et al.  Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise , 2010, Diabetes Care.

[140]  E. Porat,et al.  Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. , 2010, Journal of molecular and cellular cardiology.

[141]  J. Falck,et al.  Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARγ. , 2010, Stem cells and development.

[142]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2008. , 2010, JAMA.

[143]  K. Flegal,et al.  Prevalence of high body mass index in US children and adolescents, 2007-2008. , 2010, JAMA.

[144]  D. Zeldin,et al.  Increased CYP2J3 Expression Reduces Insulin Resistance in Fructose-Treated Rats and db/db Mice , 2010, Diabetes.

[145]  J. Falck,et al.  Epoxyeicosatrienoic Acid Agonist Rescues the Metabolic Syndrome Phenotype of HO-2-Null Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.

[146]  J. Imig,et al.  Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. , 2009, Clinical science.

[147]  R. DeFronzo,et al.  Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes , 2009, Diabetes Care.

[148]  Ferhaan Ahmad,et al.  SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. , 2009, Cardiovascular research.

[149]  R. Rezzani,et al.  Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE. , 2009, American journal of physiology. Renal physiology.

[150]  B. Hammock,et al.  14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. , 2009, Journal of medicinal chemistry.

[151]  S. Mudaliar,et al.  Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study , 2009, The Lancet.

[152]  S. Anker,et al.  Nutrition in heart failure: an update , 2009, Current opinion in clinical nutrition and metabolic care.

[153]  G. Lip,et al.  Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. , 2009, European heart journal.

[154]  E. Braunwald,et al.  Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. , 2009, Journal of the American College of Cardiology.

[155]  E. Braunwald,et al.  Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial , 2009, Circulation.

[156]  G. Mann,et al.  Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. , 2009, Cardiovascular research.

[157]  A. Spector.  Arachidonic acid cytochrome P450 epoxygenase pathway Work from my laboratory cited in this review was supported by National Institutes of Health grants HL049264 and HL072845. Published, JLR Papers in Press, October 23, 2008. , 2009, Journal of Lipid Research.

[158]  M. Maines,et al.  Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. , 2009, Trends in pharmacological sciences.

[159]  V. Positano,et al.  Heme Oxygenase-1 Induction Remodels Adipose Tissue and Improves Insulin Sensitivity in Obesity-Induced Diabetic Rats , 2009, Hypertension.

[160]  C. Pepine,et al.  Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. , 2009, Journal of the American College of Cardiology.

[161]  C. Buechler,et al.  Fatty acid‐induced induction of Toll‐like receptor‐4/nuclear factor‐κB pathway in adipocytes links nutritional signalling with innate immunity , 2009, Immunology.

[162]  Jiandie D. Lin,et al.  Paradoxical effects of increased expression of PGC-1α on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism , 2008, Proceedings of the National Academy of Sciences.

[163]  B. Nilius,et al.  Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation. , 2008, Cardiovascular research.

[164]  W. Paulus,et al.  Transcriptional and posttranslational modifications of titin: implications for diastole. , 2008, Circulation research.

[165]  N. Musi,et al.  Advances in the development of AMPK-activating compounds , 2008, Expert opinion on drug discovery.

[166]  C. Fang,et al.  Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. , 2008, American journal of physiology. Heart and circulatory physiology.

[167]  A. Agarwal,et al.  Heme oxygenase-1 deficiency promotes epithelial-mesenchymal transition and renal fibrosis. , 2008, Journal of the American Society of Nephrology : JASN.

[168]  M. Volpe,et al.  Development of heart failure in recent hypertension trials , 2008, Journal of hypertension.

[169]  W. Aronow,et al.  Treatment of Obese Diabetic Mice With a Heme Oxygenase Inducer Reduces Visceral and Subcutaneous Adiposity, Increases Adiponectin Levels, and Improves Insulin Sensitivity and Glucose Tolerance , 2008, Diabetes.

[170]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[171]  T. Lennie.  Nutrition Self-care in Heart Failure: State of the Science , 2008, The Journal of cardiovascular nursing.

[172]  L. Cassis,et al.  Local adipose tissue renin-angiotensin system , 2008, Current hypertension reports.

[173]  N. Abraham,et al.  Pharmacological and Clinical Aspects of Heme Oxygenase , 2008, Pharmacological Reviews.

[174]  W. Humphreys,et al.  Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. , 2008, Journal of medicinal chemistry.

[175]  A. Skene,et al.  Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease , 2007, Diabetes Care.

[176]  M. Gladwin,et al.  Heme Oxygenase-1 Deficiency Accelerates Formation of Arterial Thrombosis Through Oxidative Damage to the Endothelium, Which Is Rescued by Inhaled Carbon Monoxide , 2007, Circulation research.

[177]  A. Tahrani,et al.  Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? , 2007, BMJ : British Medical Journal.

[178]  N. Maulik,et al.  Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. , 2007, Free radical biology & medicine.

[179]  F. McAlister,et al.  Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review , 2007, BMJ : British Medical Journal.

[180]  E. Abel,et al.  Diabetic cardiomyopathy revisited. , 2007, Circulation.

[181]  J. Falck,et al.  Characterization of 14,15-Epoxyeicosatrienoyl-Sulfonamides as 14,15-Epoxyeicosatrienoic Acid Agonists: Use for Studies of Metabolism and Ligand Binding , 2007, Journal of Pharmacology and Experimental Therapeutics.

[182]  W. Boland,et al.  Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes , 2007, International journal of medical sciences.

[183]  A. Sher,et al.  Cooperation of Toll-like receptor signals in innate immune defence , 2007, Nature Reviews Immunology.

[184]  A. A. Spector,et al.  Action of epoxyeicosatrienoic acids on cellular function. , 2007, American journal of physiology. Cell physiology.

[185]  R. Kukreja.  Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase , 2007, British journal of pharmacology.

[186]  M. Guazzi,et al.  Sildenafil reduces L‐NAME‐induced severe hypertension and worsening of myocardial ischaemia–reperfusion damage in the rat , 2007, British journal of pharmacology.

[187]  Christian Gluud,et al.  Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. , 2007, JAMA.

[188]  N. Tewari-Singh,et al.  Tumor Necrosis Factor-α Induces Endothelial Dysfunction in Leprdb Mice , 2007 .

[189]  B. Finck,et al.  The PPAR regulatory system in cardiac physiology and disease. , 2007, Cardiovascular research.

[190]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[191]  S. Shenouda,et al.  Up-Regulation of Heme Oxygenase Provides Vascular Protection in an Animal Model of Diabetes through Its Antioxidant and Antiapoptotic Effects , 2006, Journal of Pharmacology and Experimental Therapeutics.

[192]  H. Pilegaard,et al.  Control of gene expression and mitochondrial biogenesis in the muscular adaptation to endurance exercise. , 2006, Essays in biochemistry.

[193]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[194]  N. Abraham,et al.  Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. , 2006, American journal of physiology. Heart and circulatory physiology.

[195]  J. B. Kim,et al.  Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. , 2006, Biochemical and biophysical research communications.

[196]  D. Drucker,et al.  Glucagon and glucagon-like peptide receptors as drug targets. , 2006, Current pharmaceutical design.

[197]  N. Abraham,et al.  Endothelial Dysfunction and Hypertension in Rats Transduced With CYP4A2 Adenovirus , 2006, Circulation research.

[198]  Jawed Alam,et al.  Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. , 2006, Physiological reviews.

[199]  D. Kelly,et al.  PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. , 2006, The Journal of clinical investigation.

[200]  R. Scarpulla,et al.  Nuclear control of respiratory gene expression in mammalian cells , 2006, Journal of cellular biochemistry.

[201]  S. Ryter,et al.  CO as a cellular signaling molecule. , 2006, Annual review of pharmacology and toxicology.

[202]  R. Shannon,et al.  Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. , 2005, American journal of physiology. Heart and circulatory physiology.

[203]  P. Cozzone,et al.  Noninvasive Characterization of Myocardial Blood Flow in Diabetic, Hypertensive, and Diabetic–Hypertensive Rats Using Spin‐Labeling MRI , 2005, Microcirculation.

[204]  S. Kihara,et al.  Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms , 2005, Nature Medicine.

[205]  L. Rodella,et al.  Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes. , 2005, American journal of physiology. Heart and circulatory physiology.

[206]  N. Abraham,et al.  D-4F Induces Heme Oxygenase-1 and Extracellular Superoxide Dismutase, Decreases Endothelial Cell Sloughing, and Improves Vascular Reactivity in Rat Model of Diabetes , 2005, Circulation.

[207]  Christoph Handschin,et al.  Metabolic control through the PGC-1 family of transcription coactivators. , 2005, Cell metabolism.

[208]  Jiandie D. Lin,et al.  Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. , 2005, Cell metabolism.

[209]  Anindita Das,et al.  Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and Apoptosis , 2005, Journal of Biological Chemistry.

[210]  H. Krumholz,et al.  Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study , 2005, Circulation.

[211]  R. Scarpulla,et al.  Control of Mitochondrial Transcription Specificity Factors (TFB1M and TFB2M) by Nuclear Respiratory Factors (NRF-1 and NRF-2) and PGC-1 Family Coactivators , 2005, Molecular and Cellular Biology.

[212]  J. Liao,et al.  Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. , 2005, Archives of biochemistry and biophysics.

[213]  S. Rathore,et al.  The obesity paradox: body mass index and outcomes in patients with heart failure. , 2005, Archives of internal medicine.

[214]  L. Rodella,et al.  Overexpression of human heme oxygenase-1 attenuates endothelial cell sloughing in experimental diabetes. , 2004, American journal of physiology. Heart and circulatory physiology.

[215]  N. Abraham,et al.  Transfection and Functional Expression of CYP4A1 and CYP4A2 Using Bicistronic Vectors in Vascular Cells and Tissues , 2004, Journal of Pharmacology and Experimental Therapeutics.

[216]  J. Holst,et al.  Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.

[217]  M. Geiser,et al.  Evidence for Ligand-independent Transcriptional Activation of the Human Estrogen-related Receptor α (ERRα) , 2004, Journal of Biological Chemistry.

[218]  R. Kinobe,et al.  Peroxynitrite-mediated inactivation of heme oxygenases , 2004, BMC pharmacology.

[219]  F. Roudot-thoraval,et al.  N-Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-&agr; Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats , 2004, Circulation.

[220]  Jiandie D. Lin,et al.  Defects in Adaptive Energy Metabolism with CNS-Linked Hyperactivity in PGC-1α Null Mice , 2004, Cell.

[221]  D. Randall,et al.  Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[222]  H. Weiss,et al.  Bioenergetic remodeling of heart mitochondria by thyroid hormone , 2004, Molecular and Cellular Biochemistry.

[223]  V. Giguère,et al.  Estrogen-Related Receptor α Directs Peroxisome Proliferator-Activated Receptor α Signaling in the Transcriptional Control of Energy Metabolism in Cardiac and Skeletal Muscle , 2004, Molecular and Cellular Biology.

[224]  J. Falck,et al.  14,15-EET analogs: characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. , 2004, Pharmacological research.

[225]  N. Jessen,et al.  AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. , 2004, Biochemical and biophysical research communications.

[226]  J. Saffitz,et al.  Cardiac-Specific Induction of the Transcriptional Coactivator Peroxisome Proliferator-Activated Receptor &ggr; Coactivator-1&agr; Promotes Mitochondrial Biogenesis and Reversible Cardiomyopathy in a Developmental Stage-Dependent Manner , 2004, Circulation research.

[227]  N. Abraham,et al.  Heme oxygenase-1 prevents superoxide anion-associated endothelial cell sloughing in diabetic rats. , 2004, Biochemical and biophysical research communications.

[228]  R. Shannon,et al.  Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion , 2004, Circulation.

[229]  R. Scarpulla,et al.  Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. , 2004, Genes & development.

[230]  T. Levade,et al.  N-Acetylcysteine Prevents the Deleterious Effect of Tumor Necrosis Factor-&agr; on Calcium Transients and Contraction in Adult Rat Cardiomyocytes , 2004, Circulation.

[231]  A. Aljada,et al.  Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. , 2003, Diabetes.

[232]  M. Metra,et al.  β‐Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long‐term effects of atenolol vs. nebivolol , 2003, European journal of heart failure.

[233]  O. Febo,et al.  Is nutritional intake adequate in chronic heart failure patients? , 2003, Journal of the American College of Cardiology.

[234]  T. Kushida,et al.  Heme Oxygenase-1 Attenuates Glucose-Mediated Cell Growth Arrest and Apoptosis in Human Microvessel Endothelial Cells , 2003, Circulation research.

[235]  S. Del Prato,et al.  Reducing insulin resistance with metformin: the evidence today. , 2003, Diabetes & metabolism.

[236]  F. Bach,et al.  Heme oxygenase-1: unleashing the protective properties of heme. , 2003, Trends in immunology.

[237]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[238]  A. Butte,et al.  Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[239]  T. Nakao,et al.  Role of JNK, p38, and ERK in Platelet-Derived Growth Factor–Induced Vascular Proliferation, Migration, and Gene Expression , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[240]  Anastasia Kralli,et al.  The Transcriptional Coactivator PGC-1 Regulates the Expression and Activity of the Orphan Nuclear Receptor Estrogen-Related Receptor α (ERRα)* , 2003, The Journal of Biological Chemistry.

[241]  John E Hall,et al.  The kidney, hypertension, and obesity. , 2003, Hypertension.

[242]  P. Puigserver,et al.  Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. , 2003, Endocrine reviews.

[243]  M. Hentschke,et al.  PGC-1 and PERC, coactivators of the estrogen receptor-related receptor gamma. , 2002, Biochemical and biophysical research communications.

[244]  L. Nolte,et al.  Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC‐1 , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[245]  Megan Jehn,et al.  Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). , 2002, Hypertension.

[246]  Daniel P. Kelly,et al.  Peroxisome Proliferator-activated Receptor Coactivator-1α (PGC-1α) Coactivates the Cardiac-enriched Nuclear Receptors Estrogen-related Receptor-α and -γ , 2002, The Journal of Biological Chemistry.

[247]  S. Ryter,et al.  Heme oxygenase-1: molecular mechanisms of gene expression in oxygen-related stress. , 2002, Antioxidants & redox signaling.

[248]  E. Gulve,et al.  Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. , 2002, Biochemical and biophysical research communications.

[249]  S. Ryter,et al.  Heme oxygenase/carbon monoxide signaling pathways: Regulation and functional significance , 2002, Molecular and Cellular Biochemistry.

[250]  A. Agarwal,et al.  Heme oxygenase and the kidney. , 2002, DNA and cell biology.

[251]  M. Maines,et al.  Human Biliverdin Reductase Is a Leucine Zipper-like DNA-binding Protein and Functions in Transcriptional Activation of Heme Oxygenase-1 by Oxidative Stress* , 2002, The Journal of Biological Chemistry.

[252]  M. Kilberg,et al.  Glucose Deprivation Induces Heme Oxygenase-1 Gene Expression by a Pathway Independent of the Unfolded Protein Response* , 2002, The Journal of Biological Chemistry.

[253]  G. Drummond,et al.  Sn-Mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah's Witness newborns as an alternative to exchange transfusion. , 2001, Pediatrics.

[254]  A. Kralli,et al.  PGC-1, a versatile coactivator , 2001, Trends in Endocrinology & Metabolism.

[255]  D. Zeldin.  Epoxygenase Pathways of Arachidonic Acid Metabolism* , 2001, The Journal of Biological Chemistry.

[256]  P. Scherer,et al.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.

[257]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[258]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[259]  D. Irwin.  Molecular evolution of proglucagon , 2001, Regulatory Peptides.

[260]  B. Maisch,et al.  Diabetic cardiomyopathy: fact or fiction? , 2001, Heart.

[261]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[262]  A. Choi,et al.  Heme oxygenase: colors of defense against cellular stress. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[263]  J. Pogue,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[264]  J. Saffitz,et al.  Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. , 2000, The Journal of clinical investigation.

[265]  D. Kelly,et al.  Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. , 2000, The Journal of clinical investigation.

[266]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[267]  W. Campbell.  New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. , 2000, Trends in pharmacological sciences.

[268]  J. Hall.  Pathophysiology of obesity hypertension , 2000, Current hypertension reports.

[269]  Rick B. Vega,et al.  The Coactivator PGC-1 Cooperates with Peroxisome Proliferator-Activated Receptor α in Transcriptional Control of Nuclear Genes Encoding Mitochondrial Fatty Acid Oxidation Enzymes , 2000, Molecular and Cellular Biology.

[270]  V. Mootha,et al.  Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1 , 1999, Cell.

[271]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[272]  S. Toubro,et al.  Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects , 1998, European Journal of Clinical Nutrition.

[273]  P. Puigserver,et al.  A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.

[274]  S. Tonegawa,et al.  Reduced stress defense in heme oxygenase 1-deficient cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[275]  S. Tonegawa,et al.  Heme oxygenase 1 is required for mammalian iron reutilization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[276]  N. Abraham,et al.  Heme oxygenase induction with attenuation of experimentally induced corneal inflammation. , 1997, Biochemical pharmacology.

[277]  S. Hunt,et al.  Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[278]  K. Prasad,et al.  Lipid peroxidation and activity of antioxidant enzymes in diabetic rats , 1995, Molecular and Cellular Biochemistry.

[279]  S. Mojsov,et al.  Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences , 1995, FEBS letters.

[280]  D. Carling,et al.  Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell‐permeable activator of AMP‐activated protein kinase , 1994, FEBS letters.

[281]  N. Abraham,et al.  Tin‐Mediated Heme Oxygenase Gene Activation and Cytochrome P450 Arachidonate Hydroxylase Inhibition in Spontaneously Hypertensive Rats , 1994, The American journal of the medical sciences.

[282]  S. Snyder,et al.  Carbon monoxide: a putative neural messenger. , 1993, Science.

[283]  E. Wright,et al.  Colocalization of GLUT2 Glucose Transporter, Sodium/glucose Cotransporter, and γ-Glutamyl Transpeptidase in Rat Kidney With Double-Peroxidase Immunocytochemistry , 1992, Diabetes.

[284]  R. Estabrook,et al.  Cytochrome P450 and the arachidonate cascade 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[285]  K. Miyamoto,et al.  Diabetes and glucose transporter gene expression in rat small intestine. , 1991, Biochemical and biophysical research communications.

[286]  N. Abraham,et al.  Regulation of heme oxygenase gene expression by cobalt in rat liver and kidney. , 1990, European journal of biochemistry.

[287]  G. Weir,et al.  Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3',5'-monophosphate formation. , 1990, Endocrinology.

[288]  B. Ames,et al.  Bilirubin is an antioxidant of possible physiological importance. , 1987, Science.

[289]  W. Winder,et al.  Effect of exhausting exercise on rat heart mitochondria. , 1973, The American journal of physiology.

[290]  K. Cohen,et al.  Caloric restriction ameliorates cardiomyopathy in animal model of diabetes , 2017, Experimental cell research.

[291]  N. Abraham,et al.  Translational Significance of Heme Oxygenase in Obesity and Metabolic Syndrome. , 2016, Trends in pharmacological sciences.

[292]  P. Ponikowski,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016 .

[293]  P. Mulder,et al.  Cardiovascular Consequences of Obesity and Type 2 Diabetes Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice , 2015 .

[294]  C. Chen,et al.  CYP epoxygenase 2J2 prevents cardiac fibrosis by suppression of transmission of pro-inflammation from cardiomyocytes to macrophages. , 2015, Prostaglandins & other lipid mediators.

[295]  J. Olgin,et al.  Blockade of A2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model. , 2014, Heart rhythm.

[296]  R. Kornowski,et al.  Elevated level of pro-inflammatory eicosanoids and EPC dysfunction in diabetic patients with cardiac ischemia. , 2013, Prostaglandins & other lipid mediators.

[297]  John D Imig,et al.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology. , 2012, Physiological reviews.

[298]  P. Balakumar,et al.  Healing the diabetic heart: does myocardial preconditioning work? , 2012, Cellular signalling.

[299]  M. Movahed,et al.  Diabetic cardiomyopathy. , 2010, Journal of cardiac failure.

[300]  Xinliang Ma,et al.  Protective vascular and myocardial effects of adiponectin , 2009, Nature Clinical Practice Cardiovascular Medicine.

[301]  L. Appel,et al.  Scientific Statement From the American Heart Association State of the Science: Promoting Self-Care in Persons With Heart Failure: A , 2009 .

[302]  R. DeFronzo,et al.  Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. , 2008, Journal of the American Society of Nephrology : JASN.

[303]  K. Kario,et al.  Comparison of the Effects of Pioglitazone and Metformin on Insulin Resistance and Hormonal Markers in Patients with Impaired Glucose Tolerance and Early Diabetes , 2007, Hypertension Research.

[304]  J. Falck,et al.  11,12-epoxyeicosatrienoic acid stimulates heme-oxygenase-1 in endothelial cells. , 2007, Prostaglandins & other lipid mediators.

[305]  B. Chaitman,et al.  Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. , 2006, European heart journal.

[306]  C. Gullion,et al.  The incidence of congestive heart failure associated with antidiabetic therapies , 2005, Diabetes/metabolism research and reviews.

[307]  G. Fonarow,et al.  Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. , 2005, American heart journal.

[308]  A. Kappas.  A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. , 2004, Pediatrics.

[309]  W. MacNee,et al.  Oxidative stress and TNF-α induce histone acetylation and NF-κB/AP-1 activation in alveolar epithelial cells: Potential mechanism in gene transcription in lung inflammation , 2004, Molecular and Cellular Biochemistry.

[310]  C. R. Wilson,et al.  Obesity and the risk of heart failure. , 2002, The New England journal of medicine.

[311]  J. Zierath,et al.  5-aminoimidazole-4-carboxy-amide-1-beta-D-ribofuranoside treatment ameliorates hyperglycaemia and hyperinsulinaemia but not dyslipidaemia in KKAy-CETP mice. , 2001, Diabetologia.

[312]  N. Abraham,et al.  The Biological Significance and Physiological Role of Heme Oxygenase , 1996 .

[313]  B. Maisch.  Ventricular remodeling. , 1996, Cardiology.

[314]  N. Abraham,et al.  Roles of renal cytochrome P450-dependent arachidonic acid metabolites in hypertension. , 1992, The Tohoku journal of experimental medicine.

[315]  V. Dennis,et al.  Phosphate and glucose transport in the proximal convoluted tubule: mutual dependency on sodium. , 1978, Advances in experimental medicine and biology.

[316]  J. Holloszy.  Adaptation of skeletal muscle to endurance exercise. , 1975, Medicine and science in sports.